News

16/05/13: Stallergenes and DBV Technologies enter into partnership for the development of innovative treatment of respiratory allergies; Partnership to develop immunotherapy treatments for respiratory allergies...; [more]

08/03/13: Commercialization of Oralair in the US: possible cooperation with Greer Laboratories, Inc.; Stallergenes S.A. (Euronext Paris CAC small) plans to evaluate possible...; [more]

STALLERGENES, biopharmaceutical company

Major player in its market, Stallergenes established sublingual immunotherapy and remains the world leader in this area. Since 2003, the company is committed to the Stalair® development program, creating a new therapeutic class that covers 80% of respiratory allergies.

Measure the impact
of my allergy

STALLERGENES celebrates its 50th Anniversary

For 50 years, Stallergenes is specialized in the treatment of severe respiratory allergies, such as severe rhino conjunctivitis and rhinitis as well as allergic asthma.

With a total workforce of 1 100 employees, Stallergenes is present in 18 countries and distributes its products in more than 50 countries.

Useful links

2012 Sales

EBE (European Biopharmaceutical Enterprises)

G5 Health (French Association on Healthcare issues)

ARES LIFE SCIENCES